Quick Answer
AEON Biopharma, Inc. reported Net Income of -$39.22 million for fiscal year 2025.
AEON Biopharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$39.22M -193.4% |
$42.01M | — | -$52.56M -740.9% |
$8.20M +228662.7% |
-$3.6K |
| Diluted EPS | -$3.95 -105.4% |
$72.93 | — | -$0.38 | — | — |
| Total Assets | $5.56M +77.0% |
$3.14M -54.1% |
$6.84M -36.5% |
$10.78M -96.1% |
$276.95M +341813.0% |
$81.0K |
| Cash and Equivalents | $3.01M +23023.1% |
$13.0K -100.0% |
$31.20M +220.1% |
$9.75M +1859.3% |
$497.4K | — |
| Stockholders Equity | -$55.03M -92.6% |
-$28.57M -117.1% |
$167.14M +158.1% |
-$287.50M -1598.2% |
-$16.93M -79167.1% |
$21.4K |
| R&D Expense | $4.09M -71.1% |
$14.18M | — | $34.75M | — | — |
| Operating Income | -$12.80M -117.5% |
$72.98M | — | -$48.43M -2401.6% |
-$1.94M -53856.0% |
-$3.6K |
| Shares Outstanding | 12.11M +2079.2% |
555,511 +7.6% |
516,404 -99.6% |
138.83M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$4.54M | +26.5% | +31.7% |
| Diluted EPS | September 30, 2025 | -$0.39 | +96.5% | +35.0% |
| Total Assets | September 30, 2025 | $8.73M | +118.1% | -25.1% |
| Cash and Equivalents | September 30, 2025 | $5.93M | +1003.7% | -29.8% |
| Stockholders Equity | September 30, 2025 | -$19.87M | +38.1% | -25.4% |
| R&D Expense | September 30, 2025 | $597.0K | -38.6% | -43.9% |
| Operating Income | September 30, 2025 | -$2.49M | +37.9% | +42.5% |
| Shares Outstanding | September 30, 2025 | 11.64M | -70.6% | +0.9% |
- AEON Biopharma, Inc. reported Net Income of -$39.22 million for fiscal year 2025.
- AEON Biopharma, Inc. showed a decrease of -193.4% in Net Income compared to the prior fiscal year.
- AEON Biopharma, Inc. reported Diluted EPS of $3.95 per share (loss) for fiscal year 2025.
- AEON Biopharma, Inc. showed a decrease of -105.4% in Diluted EPS compared to the prior fiscal year.
- AEON Biopharma, Inc. reported Total Assets of $5.56 million for fiscal year 2025.
- AEON Biopharma, Inc. showed an increase of +77.0% in Total Assets compared to the prior fiscal year.
- AEON Biopharma, Inc. reported Cash and Equivalents of $3.01 million for fiscal year 2025.
- AEON Biopharma, Inc. showed an increase of +23023.1% in Cash and Equivalents compared to the prior fiscal year.
- AEON Biopharma, Inc. reported Stockholders Equity of -$55.03 million for fiscal year 2025.
- AEON Biopharma, Inc. showed a decrease of -92.6% in Stockholders Equity compared to the prior fiscal year.
- AEON Biopharma, Inc. reported R&D Expense of $4.09 million for fiscal year 2025.
- AEON Biopharma, Inc. showed a decrease of -71.1% in R&D Expense compared to the prior fiscal year.
- AEON Biopharma, Inc. reported Operating Income of -$12.80 million for fiscal year 2025.
- AEON Biopharma, Inc. showed a decrease of -117.5% in Operating Income compared to the prior fiscal year.
- AEON Biopharma, Inc. reported Shares Outstanding of 12.11 million shares for fiscal year 2025.
- AEON Biopharma, Inc. showed an increase of +2079.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: